Clinical trials
ClinicalTrials.gov
Below, you can find a listing of all open Phase III trials concerning cancer retrieved by www.clinicaltrials.gov, which is a register of federally and privately supported clinical trials conducted worldwide.
You can search this list by entering a type of cancer, by selecting a specific country, by entering a keyword or the NCT code of the trial you are looking for. By combining search options, you will get more refined results.
For instance, as a German breast cancer patient, you can enter breast cancer as a type of cancer and search for clinical trials in Germany.
Within a selected trial, you can look for other locations, should you be interested in clinical trials in another country.
Your selected trial will have a link to the original page on clinicaltrials.gov which you should consult to get more information about the trial. Reliable Cancer Therapies weekly selects the clinical trials available for cancer.
This section of the website is only available in English.
One of the greatest problems in renal transplantation is the shortage of donor kidneys.
Kidneys of non-heart-beating donors (NHB) are a possible solution, but transplantation is
accompanied with a high percentage of acute renal failure, caused by ischemia-reperfusion
injury. The increased ischemia-reperfusion injury results in an increased immune activation,
which can lead to more injury of the kidney and additional acute rejections. The hypothesis
of this trial is...
The present study is a multicenter, prospective phase III-study comparing dose-reduced
versus standard conditioning followed by allogeneic stem cell transplantation from related
or unrelated donors in patients with MDS or secondary AML.
The hypothesis is that dose-reduced conditioning will reduce the non-relapse mortality from
40% to 20% at one year after allogeneic stem cell transplantation.
This study is designed as a phase III, randomized, double-blind, placebo-controlled trial to
explore the effect of maintenance therapy with lenalidomide versus placebo on
progression-free survival (PFS) in patients treated with R-CHOP responding to induction
therapy
For the primary efficacy variable, PFS, an improvement in median PFS from 38.6 months for
Treatment Arm B to 54 months for Treatment Arm A (corresponding to a 2-year PFS of 65% vs
73.6%), is...
This study is designed as a phase III, randomized, double-blind, placebo-controlled trial to
explore the effect of maintenance therapy with lenalidomide versus placebo on
progression-free survival (PFS) in patients treated with R-CHOP responding to induction
therapy
For the primary efficacy variable, PFS, an improvement in median PFS from 38.6 months for
Treatment Arm B to 54 months for Treatment Arm A (corresponding to a 2-year PFS of 65% vs
73.6%), is...
This study is designed as a phase III, randomized, double-blind, placebo-controlled trial to
explore the effect of maintenance therapy with lenalidomide versus placebo on
progression-free survival (PFS) in patients treated with R-CHOP responding to induction
therapy
For the primary efficacy variable, PFS, an improvement in median PFS from 38.6 months for
Treatment Arm B to 54 months for Treatment Arm A (corresponding to a 2-year PFS of 65% vs
73.6%), is...
This study is designed as a phase III, randomized, double-blind, placebo-controlled trial to
explore the effect of maintenance therapy with lenalidomide versus placebo on
progression-free survival (PFS) in patients treated with R-CHOP responding to induction
therapy
For the primary efficacy variable, PFS, an improvement in median PFS from 38.6 months for
Treatment Arm B to 54 months for Treatment Arm A (corresponding to a 2-year PFS of 65% vs
73.6%), is...
This study is designed as a phase III, randomized, double-blind, placebo-controlled trial to
explore the effect of maintenance therapy with lenalidomide versus placebo on
progression-free survival (PFS) in patients treated with R-CHOP responding to induction
therapy
For the primary efficacy variable, PFS, an improvement in median PFS from 38.6 months for
Treatment Arm B to 54 months for Treatment Arm A (corresponding to a 2-year PFS of 65% vs
73.6%), is...
This study is designed as a phase III, randomized, double-blind, placebo-controlled trial to
explore the effect of maintenance therapy with lenalidomide versus placebo on
progression-free survival (PFS) in patients treated with R-CHOP responding to induction
therapy
For the primary efficacy variable, PFS, an improvement in median PFS from 38.6 months for
Treatment Arm B to 54 months for Treatment Arm A (corresponding to a 2-year PFS of 65% vs
73.6%), is...
This study is designed as a phase III, randomized, double-blind, placebo-controlled trial to
explore the effect of maintenance therapy with lenalidomide versus placebo on
progression-free survival (PFS) in patients treated with R-CHOP responding to induction
therapy
For the primary efficacy variable, PFS, an improvement in median PFS from 38.6 months for
Treatment Arm B to 54 months for Treatment Arm A (corresponding to a 2-year PFS of 65% vs
73.6%), is...
This study is designed as a phase III, randomized, double-blind, placebo-controlled trial to
explore the effect of maintenance therapy with lenalidomide versus placebo on
progression-free survival (PFS) in patients treated with R-CHOP responding to induction
therapy
For the primary efficacy variable, PFS, an improvement in median PFS from 38.6 months for
Treatment Arm B to 54 months for Treatment Arm A (corresponding to a 2-year PFS of 65% vs
73.6%), is...
This site complies with the HONcode standard for trustworthy health information:
verify here.
All RCT News
- 1 of 5
- ››